13F Holdings
中文EN

CNSY CERENOME, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1095981 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-32.9%
TTM net income YoY-47.4%
TTM EPS YoY143.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-832.6%
Net margin-859.5%
FCF margin-813.5%
EBITDA margin-817.7%

Returns

ROE-1,468.0%
ROA-196.4%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets107.6%
Debt / equity—
Current ratio0.61x
Interest coverage-815.92x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue39.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5.21M$5.82M$4.91M——
R&D expense$8.38M$10.58M$9.69M$9.70M$5.32M
SG&A expense$12.13M$9.94M$8.54M$10.24M$6.85M
Operating income-$15.30M-$14.70M-$13.32M-$19.71M-$12.49M
Interest expense$548,000$179,000$395,000$711,000$932,000
Pretax income-$22.39M-$12.98M———
Income tax$0$0$0$0$0
Net income-$22.39M-$12.98M-$13.32M-$20.27M-$13.40M
EBITDA-$14.85M-$13.82M-$12.69M-$19.09M-$12.10M
EPS (basic)-0.29-1.95-4.24-11.58-1.11
EPS (diluted)-0.29-2.34-4.24-11.58-1.11
Weighted avg. shares (diluted)77.80M7.70M3.14M1.75M12.09M
Balance sheet
Cash & equivalents$4.26M$76,000$8.55M$18.12M$18.40M
Short-term investments$4.36M$3.53M———
Current assets$14.85M$5.26M$9.83M$21.82M$19.72M
PP&E, net$257,000$448,000$906,000$1.32M$1.48M
Goodwill$372,000$372,000$372,000$372,000$372,000
Intangibles$333,000$469,000$42,000——
Total assets$16.32M$6.63M$11.39M$23.87M$21.98M
Current liabilities$12.31M$15.55M$10.73M$11.85M$5.87M
Short-term debt——$3.98M$1.61M$1.61M
Long-term debt———$3.79M$5.00M
Total debt———$5.39M$6.61M
Total liabilities$12.33M$15.58M$12.74M$17.42M$11.14M
Shareholders' equity$4.00M-$8.95M-$1.35M$6.45M$10.84M
Net debt———-$12.73M-$11.79M
Shares outstanding5.55M5.90M4.44M2.24M15.51M
Cash flow statement
Operating cash flow-$20.77M-$10.55M-$12.85M-$12.97M-$10.28M
Capital expenditure$67,000$146,000$160,000——
Free cash flow-$20.84M-$10.70M-$13.01M——
Investing cash flow-$854,000-$4.11M-$160,000-$759,000-$82,000
Financing cash flow$30.31M$6.19M$3.44M$13.45M$20.42M
Depreciation & amortization$445,000$872,000$628,000$619,000$395,000
Stock-based compensation$1.54M$550,000$569,000$606,000$606,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.